• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾嗜酸细胞瘤的闪烁扫描结果。

Scintigraphic findings of renal oncocytoma.

作者信息

Larcos G, Mullan B P, Forstrom L A

机构信息

Department of Diagnostic Radiology, Mayo Clinic, Rochester, MN 55905.

出版信息

Clin Nucl Med. 1993 Oct;18(10):884-6. doi: 10.1097/00003072-199310000-00012.

DOI:10.1097/00003072-199310000-00012
PMID:8242983
Abstract

Tc-99m DTPA scintigraphy of most renal tumors characteristically discloses a vascular mass, without retention of activity on serial images. Two cases, encountered during hypertensive work-up, are presented with vascular renal masses and persistent DTPA uptake. Oncocytoma was confirmed pathologically in both cases. The authors conclude that renal oncocytomas have a relatively distinctive scintigraphic appearance, which may permit accurate preoperative diagnosis.

摘要

大多数肾肿瘤的锝-99m二乙三胺五乙酸闪烁扫描特征性地显示为血管性肿块,在系列图像上无放射性滞留。本文报告了在高血压检查过程中遇到的2例病例,均有肾血管性肿块且二乙三胺五乙酸持续摄取。2例病例经病理证实均为嗜酸细胞瘤。作者得出结论,肾嗜酸细胞瘤具有相对独特的闪烁扫描表现,这可能有助于术前准确诊断。

相似文献

1
Scintigraphic findings of renal oncocytoma.肾嗜酸细胞瘤的闪烁扫描结果。
Clin Nucl Med. 1993 Oct;18(10):884-6. doi: 10.1097/00003072-199310000-00012.
2
The role of Tc-99m MIBI scintigraphy in clinical T1 renal mass assessment: Does it have a real benefit?Tc-99m MIBI 闪烁显像在 T1 期肾肿瘤临床评估中的作用:是否有实际获益?
Urol Oncol. 2020 Dec;38(12):937.e11-937.e17. doi: 10.1016/j.urolonc.2020.07.018. Epub 2020 Aug 26.
3
Renal oncocytoma: preoperative diagnosis using technetium 99m sestamibi imaging.肾嗜酸细胞瘤:使用锝99m甲氧基异丁基异腈显像进行术前诊断。
Urology. 1996 Jul;48(1):33-9. doi: 10.1016/s0090-4295(96)00095-7.
4
Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors.(99m)Tc- sestamibi SPECT/CT 对肾嗜酸细胞瘤和混合嗜酸细胞/嫌色细胞瘤的诊断的前瞻性评估。
Eur Urol. 2016 Mar;69(3):413-6. doi: 10.1016/j.eururo.2015.08.056. Epub 2015 Sep 18.
5
Clinical Performance of Technetium-99m-Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice.锝-99m-甲氧基异丁基异腈 SPECT/CT 成像在常规临床实践中鉴别嗜酸细胞瘤与肾细胞癌的临床性能。
J Urol. 2023 Sep;210(3):438-445. doi: 10.1097/JU.0000000000003557. Epub 2023 Jun 28.
6
Use of quantitative SPECT/CT reconstruction in Tc-sestamibi imaging of patients with renal masses.定量SPECT/CT重建技术在肾肿块患者锝- sestamibi成像中的应用。
Ann Nucl Med. 2018 Feb;32(2):87-93. doi: 10.1007/s12149-017-1222-z. Epub 2017 Dec 6.
7
Uptake of 99mTc-DTPA by a renal oncocytoma.肾嗜酸细胞瘤对99mTc-DTPA的摄取
Eur J Nucl Med. 1987;13(6):311-2. doi: 10.1007/BF00256558.
8
Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms.肾嗜酸细胞瘤:CT特征无法可靠地将嗜酸细胞瘤与其他肾肿瘤区分开来。
Clin Radiol. 2009 May;64(5):517-22. doi: 10.1016/j.crad.2008.12.011. Epub 2009 Mar 9.
9
Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma.使用99mTc-MIBI单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)鉴别肾嗜酸细胞瘤与肾细胞癌的初步经验。
Clin Nucl Med. 2015 Apr;40(4):309-13. doi: 10.1097/RLU.0000000000000670.
10
Is segmental enhancement inversion on enhanced biphasic MDCT a reliable sign for the noninvasive diagnosis of renal oncocytomas?双相 MDCT 增强扫描的节段性强化反转是否可作为无创诊断肾嗜酸细胞瘤的可靠征象?
AJR Am J Roentgenol. 2011 Oct;197(4):W674-9. doi: 10.2214/AJR.11.6463.

引用本文的文献

1
Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of Tc-sestamibi SPECT/CT.通过锝-司他比单光子发射计算机断层显像/计算机断层扫描(Tc-sestamibi SPECT/CT)对肾嗜酸细胞瘤与肾细胞癌进行视觉评估和鉴别。
EJNMMI Res. 2017 Dec;7(1):29. doi: 10.1186/s13550-017-0278-z. Epub 2017 Mar 29.
2
Acute pyelonephritis resulting in intense vascular blush during dynamic renal scintigraphy.急性肾盂肾炎导致动态肾闪烁显像时出现强烈的血管造影剂充盈。
Indian J Nucl Med. 2016 Jan-Mar;31(1):69-71. doi: 10.4103/0972-3919.172369.